Children's Hospital of The King's Daughters, located in Norfolk, Virginia, United States, is the only freestanding children's hospital in Virginia. The hospital treats infants, children, teens, and young adults aged 0–21 and even some adults who require pediatric care.

There are 206 beds in Children's Specialty Group.

During the past decade, Children's Specialty Group conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Children's Specialty Group" #1 sponsor was "Actelion" with 2 trials, followed by "Amgen" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "CSL Behring" with 1 trials sponsored and "Eisai Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Children's Specialty Group" #1 collaborator was "Canadian Heart Research Centre" with 2 trials as a collaborator, "Novartis" with 2 trials as a collaborator, "Dohmen Life Science Services" with 1 trials as a collaborator and "Parexel" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Children's Specialty Group" are "Crohn's Disease" (2 trials), "Migraine" (2 trials), "Pulmonary Arterial Hypertension" (2 trials), "Chronic Migraine in Children" (1 trials) and "Duchenne Muscular Dystrophy" (1 trials). Many other conditions were trialed in "Children's Specialty Group" in a lesser frequency.

Most popular intervention types in "Children's Specialty Group" are "Drug" (8 trials), "Other" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Erenumab Dose 1" (2 trials), "Erenumab Dose 2" (2 trials), "Erenumab Dose 3" (2 trials) and "Mirikizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Children's Specialty Group" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Children's Specialty Group". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Children's Specialty Group, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Children's Specialty Group, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Children's Specialty Group has several departments that took part in Clinical trials: "Children's Specialty Group, Division of Child & Adolescent Neurology" - 2 trials